Over recent years an additional barrier to the widespread use of new and usually expensive therapies has been introduced. Conscious of the burden placed by these therapies on drug budgets, decision makers in the health industry and regulators such as NICE in the UK increasingly look for economic evidence of the cost effectiveness of new therapies, in addition to evidence of their efficacy, quality and safety.

This barrier is often called the 4th Hurdle. THERAPYAUDIT® has been designed to help provide the data collection and audit component of the cost effectiveness argument that overcomes the barrier.

Read more about the 4th Hurdle here.